Addressing Cancer Care Disparities in Europe: Insights from the 2025 Comparator Report

By João L. Carapinha

March 27, 2025

The “Comparator Report on Cancer in Europe 2025” analyzes the landscape of cancer care across Europe. It highlights cancer care disparities persisting in different European regions and cancer types. While advances in treatment exist, many patients still struggle to access timely and effective care. Molecular diagnostics are also key for precision oncology but vary in access. Lower-income regions lack complex assays, worsening disparities in care quality.

Cancer is the world’s second-leading cause of death, with nearly 10 million deaths in 2020. The OECD’s “Health at a Glance 2023” stresses the need for better prevention and care strategies in Europe.

Rising Incidence and Reimbursement Speed

Cancer incidence in Europe rose by 58% from 1995 to 2022, reaching 3.2 million new cases yearly. Mortality rates have stabilized at 1.3-1.4 million deaths since 2008, reflecting complex factors influencing outcomes. Direct cancer treatment costs doubled from €62 billion in 1995 to €146 billion in 2023. Medicine costs now exceed 40% of total expenses, worsening access for disadvantaged groups.

Wealthier Western European countries quickly reimburse EMA-approved drugs. Meanwhile, Central and Eastern Europe face delays and restricted coverage. These cancer care disparities demand equitable policies to bridge gaps.

Implications for Health Economics and Market Access

Health Economics and Outcomes Research (HEOR) can improve cancer care access. It provides evidence to optimize resource allocation and cost-effectiveness. Frameworks like the ISPOR Value Flower could integrate societal impacts into HTA. Performance-based MEAs and multi-speed HTA processes may prioritize promising drugs while monitoring uncertain ones.

More public funding is needed for treatment optimization studies and data infrastructure. Evolving HTA methodologies should adopt a societal perspective to ensure fair access to innovative treatments.

These findings highlight the urgency of addressing cancer care disparities. HEOR can enhance equity and efficiency in healthcare. For deeper insights, explore the full report.

 

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.